Marius Giedraitis, director and founder of Balux, explains the company’s commitment to shipping high-value temperature-sensitive pharmaceuticals with quality goals of 99.5 percent of deliveries without any deviation by 2019.
Could you please introduce the main activities and operations of Balux to our international audience?
"Our niche strategy helps us to overcome this challenge because our service is not seen as a commodity in the market."
Eugenija Sutkienė of TGS Baltic, a commercial law firm operating across the Baltics, discusses the services that the organization provides to the pharmaceutical and biotech industries and what sets them…
Aki Kasvi and Mindaugas Plieskis of Janssen Baltics discuss their strategic priorities, acting as a strategic partner within the region, and ensuring that patients can access their innovative latest-generation therapies…
Lukas Savickas, advisor to the prime minister of Lithuania, highlights the changes needed for the Lithuanian life science industry to become more competitive, while discussing the opportunities awaiting companies willing…
As the Lithuanian market matures, profound shifts have been taking place in the arena of human resources and how drug developers go about identifying, acquiring and retaining the personnel they…
With over 120,000 people whose lives are affected by the disease in Lithuania; diabetes stands as one of the country’s major health issues today. Furthermore, as Marijus Valatka, general manager…
Lithuania’s biotech sector has grown by between 20 and 25 percent over the last five years and accounts for over one percent of the entire country’s GDP. Key industry stakeholders…
See our Cookie Privacy Policy Here